People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals, Medical Devices
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ArriVent Biopharma, Inc. | — | Biotechnology | Series D+ | $260.0M | $2.0B | 2022 |
| BioAge Labs, Inc. | — | Biotechnology | Series D+ | $194.4M | $2.4B | 2024 |
| Bolt Biotherapeutics, Inc. | — | Biotechnology | Series C | $178.6M | $432.9M | 2020 |
| Atsena Therapeutics, Inc. | — | Biotechnology | Series C | $146.0M | $605.7M | 2023 |
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2011 |
| Sorbent Therapeutics Inc | — | Pharmaceuticals | Series B | $58.6M | $221.0M | 2011 |
| Humanigen, Inc | — | Pharmaceuticals | Series B | $39.2M | $16.8M | 2012 |
| Dxterity Diagnostics Inc | — | Medical Devices | Seed | $8.7M | $77.0M | 2009 |
James Healy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Healy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James I. Healy | 2 | 7 |
| Carl Gordon | 1 | 24 |
| Patrick Enright | 1 | 10 |
| Vijay Pande | 1 | 9 |
| Michael Harrison | 1 | 8 |
| David Collier | 1 | 8 |
| Richard Miller | 1 | 8 |
| Scott Minick | 1 | 7 |
| Dov Goldstein | 1 | 6 |
| Rob Hopfner | 1 | 6 |
| Peter Moldt | 1 | 6 |
| Edgar G Engleman | 1 | 5 |
| Bijan Salehizadeh | 1 | 5 |
| Mahendra Shah | 1 | 5 |
| DENNIS HENNER | 1 | 5 |
| Cameron Durrant | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Jake Nunn | 1 | 5 |
| Brigitte Smith | 1 | 5 |
| Michael Dial | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.